2 weeks Ago By ABMN Staff
Russell Investments Group Ltd. raised its position in shares of Globus Medical, Inc. ( NYSE:GMED – Free Report ) by 527.
9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,645 shares of the medical device company’s stock after acquiring an additional 27,446 shares during the period. Russell Investments Group Ltd.
’s holdings in Globus Medical were worth $2,700,000 as of its most recent filing with the Securities & Exchange Commission. Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc.
grew its holdings in Globus Medical by 2.3% during the 4th quarter. Vanguard Group Inc.
now owns 10,863,834 shares of the medical device company’s stock valued at $898,548,000 after purchasing an additional 240,218 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Globus Medical by 7.
7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,804,330 shares of the medical device company’s stock valued at $231,946,000 after buying an additional 199,556 shares during the last quarter.
Geode Capital Management LLC lifted its stake in shares of Globus Medical by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,897,212 shares of the medical device company’s stock worth $156,969,000 after acquiring an additional 12,151 shares during the last quarter.
Geneva Capital Management LLC boosted its holdings in Globus Medical by 13.6% during the 4th quarter. Geneva Capital Management LLC now owns 1,815,837 shares of the medical device company’s stock valued at $150,188,000 after acquiring an additional 217,707 shares during the period.
Finally, Norges Bank bought a new position in Globus Medical in the 4th quarter valued at $117,102,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.
Globus Medical Trading Down 0.2 % Shares of NYSE GMED opened at $71.03 on Friday.
Globus Medical, Inc. has a 12-month low of $49.33 and a 12-month high of $94.
93. The stock’s fifty day simple moving average is $75.84 and its two-hundred day simple moving average is $79.
97. The stock has a market capitalization of $9.77 billion, a PE ratio of 94.
71, a price-to-earnings-growth ratio of 1.61 and a beta of 1.28.
Analyst Ratings Changes GMED has been the subject of several research analyst reports. Truist Financial decreased their target price on Globus Medical from $82.00 to $80.
00 and set a “hold” rating for the company in a research report on Friday, April 11th. Stifel Nicolaus boosted their price objective on shares of Globus Medical from $92.00 to $94.
00 and gave the company a “buy” rating in a research report on Friday, February 21st. Canaccord Genuity Group raised their target price on shares of Globus Medical from $92.00 to $101.
00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a report on Tuesday, March 18th. Finally, StockNews.
com downgraded Globus Medical from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.
com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.91. Read Our Latest Research Report on Globus Medical Globus Medical Company Profile ( Free Report ) Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. Featured Stories Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc.
( NYSE:GMED – Free Report ). Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter .
.
